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Problem: There is little information regarding the impact of the intrauterine device on 
immune parameters of the upper female reproductive tract related to risk of HIV 
acquisition.
Method of Study: We collected cervical and endometrial samples from women using 
the hormonal intrauterine device to study its effects on endocervical cytokines/
chemokine concentrations, phenotypic markers of T cells, responses of endometrial T 
cells to activation, and alterations of endometrial cellular infiltrates.
Results: Hormonal intrauterine device use was associated with: increased concentra-
tions of inflammatory cytokines/chemokines (endocervix); increased coexpression of 
CXCR4 and CCR5 (endocervix and endometrium); increased coexpression of CD38 
and HLADR (endocervix and endometrium); increased intracellular IL- 10 production 
after T- cell stimulation (endometrium); and increased density of T cells, most notably 
regulatory T cells (endometrium).
Conclusion: Hormonal intrauterine device use resulted in both inflammatory and 
immunosuppressive alterations. Further research is needed to determine the signifi-
cance of these changes for HIV risk.
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1  | INTRODUCTION
Worldwide, approximately 1 million reproductive- aged women were 
diagnosed with HIV in 2013, and among individuals under 25 years 
old, 60% of new infections were in women.1 These findings highlight 
the importance of understanding the effects of contraceptives on HIV 
risk. Intrauterine devices (IUDs) are effective long- acting and revers-
ible intrauterine contraceptives used by approximately 14% of women 
seeking to prevent pregnancy,2,3 and experts have called on the glob-
al health community to further increase access to IUDs.4 Two types 
of IUDs are currently available: the non- hormonal (copper) IUD and 
hormonal IUDs, which release the synthetic progestin levonorgestrel 
(LNG- IUD) locally within the uterine cavity, resulting in relatively low 
levels of systemic exposure.
Observational studies suggest that systemic exposure to high 
levels of some progestins may increase risk of HIV acquisition. For 
example, the time of highest ovarian production of progesterone is 
6–10 days after ovulation, which may also be a time of heightened vul-
nerability for HIV acquisition.5 Two recent meta- analyses report that 
women using the long- acting systemic progestin contraceptive, depot- 
medroxyprogesterone acetate (DMPA), are at 40–50% greater risk of 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,  provided  
the original work is properly cited.
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acquiring HIV than women using no contraceptive or non- hormonal 
contraceptives.6,7 These findings raise questions about the effects of 
progestin contraceptives with regard to susceptibility to HIV infection: 
is risk specific to DMPA, which has unique steroid actions; is risk relat-
ed to systemic delivery of progestin; or is risk related to long- term 
continuous progestin exposure? Thus, it is important to more fully 
understand the effects of locally released LNG from the LNG- IUD 
because IUD contraceptives are highly effective and increasingly used.
The biological basis for a possible association between progestins 
and HIV risk is not well understood. Some in vitro studies have sug-
gested that endogenous progesterone may lead to increased markers 
of HIV susceptibility.5,8 However, the effect of exogenous progestins 
on immune function differs by progestin type.9 There is little infor-
mation regarding the possible impact of LNG on innate and adaptive 
immune responses in the female reproductive tract. Additionally, IUDs 
are foreign bodies that result in local inflammation in the uterus, which 
may contribute to both pre- and post- fertilization contraceptive effec-
tiveness.10–12 Inflammation resulting from the IUD could also result in 
recruitment of HIV target cells, increasing HIV susceptibility.
Any effect of LNG- IUDs on susceptibility to HIV infection has not 
been evaluated rigorously in epidemiologic studies. The limited research 
that is available has not indicated an association of use of the copper- 
containing IUD with an increased risk of HIV infection, but more com-
plete assessment is needed.13 The World Health Organization (WHO) 
medical eligibility criteria for contraceptive use states, “women at high 
risk of acquiring HIV can generally use LNG- IUDs,” indicating that “the 
advantages of using this method generally outweigh the theoretical 
or proven risks”.14 In 2012, the WHO convened a technical panel to 
address ongoing concerns that hormonal contraceptives might increase 
the risk of HIV infection. This panel concluded that there is an urgent 
need for further research in both epidemiology and basic science to 
evaluate effects of hormonal contraceptives on HIV susceptibility.15
The purpose of this study was to determine the effect of a commonly 
used progestin- releasing foreign body, the LNG- IUD, on the properties of 
mucosal immunity of the upper female reproductive tract. To characterize 
the unperturbed immune microenvironment, the control group consisted 
of samples from women not using hormonal or intrauterine contraception 
that were collected at the time of peak progesterone levels (6–10 days 
after ovulation). We studied levels of cytokines/chemokines in the endo-
cervical canal, phenotypic markers of endocervical and endometrial T 
cells, responses of endometrial T cells to activation, and the characteris-
tics of endometrial cellular infiltrates, in order to provide a comprehensive 
characterization of the effects of LNG- IUD use on the immune microenvi-
ronment of mucosal sites that may support HIV transmission.
2  | MATERIALS AND METHODS
2.1 | Study design
This is a cross- sectional non- randomized comparison of women using 
LNG- IUD with women using no hormonal contraception. The UCSF 
Committee on Human Research approved the study protocol, recruit-
ing, and consent materials (approval # 10- 01063).
2.2 | Recruitment of human volunteers
Healthy women volunteers from San Francisco and the greater Bay Area 
were recruited via flyers placed in a variety of venues and advertise-
ments in local publications. Participants agreed to refrain from using 
vaginal products (creams, douches) for at least 10 days prior to study 
biopsies. Additionally, participants agreed to either abstain from vaginal 
intercourse or to use non- lubricated condoms for 72 hr prior to biopsy 
procedures. Women in the LNG- IUD groups were required to have had 
the IUD in place for at least 6 months (Table 1). Women in the control 
group reported no use of exogenous sex steroids for at least 3 months 
and a history of at least three normal and consecutive menstrual periods 
since discontinuation. In addition, if they gave birth in the past year, 
women in the control group were required to have a history of at least six 
normal and consecutive menstrual periods. Exclusion criteria included: 
age <18 or ≥45 years, positive HIV serology, positive urine nucleic acid 
amplification test for Neisseria gonorrheae or Chlamydia trachomatis, cur-
rent or recent pregnancy or breastfeeding, recent gynecological symp-
toms, recent history of irregular menstrual cycles and/or use of vaginal 
products, current or frequent genital herpes recurrences, an abnormal 
cervical cytology in past year, use of other hormonal treatments in past 
year, use of systemic corticosteroids or immune- modulating therapies, 
or daily use of non- steroidal anti- inflammatory agents. Also excluded 
were women unwilling/unable to refrain from vaginal intercourse dur-
ing the 72 hr before specimen collection. Women received payment to 
compensate for time and effort required for study participation.
2.3 | Clinical study procedures
Women in the control group were instructed to measure their urine 
for luteinizing hormone (LH) detection using a home detection kit 
(Clearblue® Ovulation Test DIGITAL, Proctor & Gamble, Cincinnati, 
OH, USA). Within 7–11 days of urine LH detection (i.e., after ovula-
tion), a study visit occurred for collection of study specimens. Prior 
to specimen collection, participants were asked whether they had 
engaged in vaginal intercourse within the prior 72 hr, and if they had, 
the visit was canceled and the participants were asked to reschedule 
during the subsequent menstrual cycle. Peripheral blood was collect-
ed in EDTA tubes, and serum progesterone was measured to validate 
the occurrence of ovulation. A speculum was inserted into the vagina, 
the cervix was visualized, and assessment made for the presence of 
vaginitis or cervicitis. If vaginal discharge was present, a wet mount 
was performed. If bacterial vaginosis, candidiasis, or trichomoniasis 
was diagnosed, the participant was offered treatment and biopsies 
were not performed. If the exam was normal, the following specimens 
were collected: endocervical fluid via wick (an ophthalmic sponge 
[Merocel eye spears, Beaver Visitec International, Waltham, MA, USA] 
inserted into the canal for 90 s, followed by a second identical col-
lection); endocervical sample using a endocervical cytobrush sample 
(Cytobrush® Plus Cell collector, CooperSurgical, Trumbull, CT, USA) 
turned three times; a cervical biopsy (performed at the transformation 
zone if visible or at the os using a Mini- Tischler punch biopsy forceps); 
and an endometrial biopsy using with a 3- mm cannula (Miltex brand 
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Softflex) inserted through the internal os into the endometrial cavity. 
For the latter procedure, if insertion of the cannula was difficult, local 
anesthesia was provided via cervical injection with lidocaine, and then 
a tenaculum was applied to the ectocervix. A second pass with the 
curette was made if the amount of tissue was observed to be insuf-
ficient after the first pass.
2.4 | Endocervical wick cytokine/chemokine 
measurements
Endocervical wick samples were snap- frozen at the time of collec-
tion and stored at −80°C until analysis in bulk (Fig. 1). Wick samples 
were weighed and then extracted following published techniques into 
300 μL ice- cold extraction buffer (PBS, 0.25 mol/L NaCl + 0.1 mg/mL 
aprotinin), centrifuged, and extracted a second time in 300 μL of extrac-
tion buffer.16 Wicks were allowed to air- dry for 24 hr, then weighed 
again; the dry wick weight was subtracted from the initial wet weight 
to determine the net weight (i.e., volume of fluid extracted from each 
wick). Two wick samples were collected consecutively from each par-
ticipant, and the two samples were pooled after extraction for each 
participant for analysis. Samples were assayed on the Milliplex panel 
(Millipore, Billerica, MA, USA) for the following cytokines: IFNalpha2, 
IFNgamma, IL- 10, IL- 12p70, IL- 1alpha, IL- 1beta, IL- 6, IL- 8, MCP1, 
MIP1alpha, MIP1beta, RANTES, and TNFalpha. The plates were read 
on a Bio- Plex Suspension Array Reader (Bio- Rad Laboratories Inc, 
Hercules, CA, USA). Protein concentrations measured in the assays 
were multiplied by the dilution factor ([net wick weight + 600] divided 
by [net wick weight]) to calculate the concentration (pg/mL) of each 
factor in the wick fluid.
2.5 | Phenotypic and functional assays of 
cervical and endometrial T cells
2.5.1 | Mononuclear cell isolation
Samples of blood, endocervical brushings, and endometrial biopsies 
collected at UCSF were transported on ice to UC Davis to arrive within 
3–4 hr of collection (Figs 2–4). Upon arrival, peripheral blood mono-
nuclear cells (PBMC) were isolated by Ficoll–Hypaque (Pfizer, New 
York, NY, USA) density gradient centrifugation, and washed in PBS. 
Mononuclear cells from endocervical brushings were isolated by rub-
bing the brushes together, pipetting several times, passing through a 
70- μm nylon cell strainer (Becton Dickinson, Bedford, MA, USA) and 
washing in complete medium [RPMI- 1640 supplemented with 15% 
FBS, penicillin (100 U/mL), streptomycin (100 μg/mL), and glutamine 
(2 mmol/L)]. Endometrial biopsies were subjected to 2–3 rounds of 
collagenase type II digestion (0.5 mg/mL; Sigma- Aldrich, St. Louis, 
MO, USA), followed by mechanical disruption using an 18- gauge 
blunt- end needle and passage through a 70- μm nylon cell strainer. The 
pooled cells were washed in complete medium. Red blood cell lysis 
was performed as needed on PBMC, endometrium and endocervical 
cells using ammonium chloride–potassium carbonate–EDTA (ACK).
2.5.2 | Monoclonal antibodies for flow cytometry
Fluorochrome- labeled monoclonal antibodies used for the phenotypic 
and intracellular staining assay included CD3 (clone UCHT1), CD4 
(clone RPA- T4), CD8 (clone SK1), CCR7 (clone 3D12), CXCR4 (clon-
e12G5), CCR5 (clone 2D7), CD8 (clone RPA- T8), IFN- γ (clone B27), 
FIGURE  1 Compares values for 13 cytokines, chemokines, and innate immune factors in endocervical fluids from controls (n=24) and LNG- IUD 
users (n=19). Fluids were collected from participants by insertion of an ophthalmic sponge [Merocel] into the endocervical canal for 90 s; fluids were 
extracted and analyzed on a Milliplex platform as described in Methods. Panel (a) age- adjusted mean biomarker concentrations (circles) and 95% 
confidence intervals (bars) from controls (blue) and LNG- IUD users (red). Concentration is represented on a log scale in pg/ml, ordered by biomarker 
concentration in controls from lowest (y- axis top) to highest (y- axis bottom). Panel (b) the mean fold- change (circle) and 95% confidence intervals 
(bars) of values from LNG- IUD users compared to control for each biomarker. Specific P- values are indicated for fold- change with P- values <.10
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TNFalpha (clone MAb11), and MIP- 1beta (clone D21- 1351) from 
Becton Dickinson Pharmingen (San Diego, CA, USA); CD45RA (2H4) 
and CD4 (clone T4D11) from Beckman Coulter (Fullerton, CA, USA); 
CD38 (clone HB7), CD107 (clone H4A3), and IL- 10 (clone JES3- 19F1) 
from BD Biosciences (San Jose, CA, USA); HLADR (clone TU36) and 
aqua amine reactive dye from Invitrogen (Carlsbad, CA, USA); CD66b 
(G10F5) Biolegend (San Diego, CA, USA); and IL- 17 (clone eBio-
64CAP17) and IL- 2 (clone MQ1- 17H12) from eBioscience (San Diego, 
CA, USA). Optimum antibody titers were determined empirically for 
each antibody based on preliminary titration experiments using serial 
dilutions, which included the manufacturers’ recommended amounts. 
Fluorescence- minus- one (FMO) controls were utilized as needed to 
establish positive cutoffs.17 Flow cytometry data were acquired on an 
LSRII (BD Immunocytometry Systems, San Jose, CA, USA) equipped 
with 405, 488, and 643- nm lasers and utilizing FACSDIVA software 
(BDIS). Analysis of cytometry data was performed with FlowJo soft-
ware (TreeStar, Ashland, OR, USA). Results were recorded as the per-
centage of CD4+ or CD8+ T cells expressing a given surface marker or 
combination of markers.
2.5.3 | Phenotypic and intracellular cytokine 
staining and flow cytometry
For cell surface phenotyping, endocervical and endometrial cells were 
stained immediately following sample processing and leukocyte isola-
tion as previously described (Table 2; Fig. 4).18 For measurement of 
intracellular cytokine production, endometrial cells were rested over-
night in complete medium prior to performing stimulation assays. The 
next morning, 2–3 × 106 cells in 200 microliters complete medium 
F IGURE  2 Flow cytometry gating used in the analysis of endocervical and endometrial T- cell phenotypes. After initial gating of lymphocytes 
(based on forward vs side scatter) and doublet discrimination, dead cells were excluded by staining with live/dead viable amine; viable cells that 
were CD3+CD66b− (not shown) were then subdivided into CD4+ or CD8+ populations. The resulting CD4+ or CD8+ T cells were then assessed 
for expression of three pairs of phenotypic markers, as described in the text. Shown from left to right, these were as follows: differentiation 
markers CCR7 and CD45RA; activation markers CD38 and HLA- DR; chemokine receptors CCR5 and CXCR4. Quadrant gates were drawn 
based on fluorescence- minus- one (FMO) controls. Numbers in each quadrant indicate percentages of CD4+ or CD8+ T cells expressing various 
combinations of markers. Data shown are from a representative participant using LNG- IUD
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were treated with anti- CD107, monensin (1 μmol/L GolgiStopTM; 
BD Biosciences), brefeldin A (5 mg/mL, Sigma-Aldrich, St. Louis, MO, 
USA), and either staphylococcal enterotoxin B (0.5 μg/mL) or phor-
bol myristate acetate (PMA, 50 ng/mL) and ionomycin (500 ng/mL). 
Complete medium containing anti- CD107, monensin, and brefeldin A 
served as a negative control. Following a five- hour incubation, cells 
were incubated for 5 min in phosphate- buffered saline (PBS)/2% 
FCS/0.5 mmol/L EDTA, stained for surface markers and cell viabil-
ity using aqua amino reactive dye in PBS/2% FCS for 20 min at 4°C, 
fixed in 4% formaldehyde, then permeabilized using FACS Perm 2 
(BD Biosciences). Cells were then washed in PBS/2% fetal calf serum, 
stained for intracellular cytokines and CD3, washed again, then stored 
at 4°C in PBS/1% formaldehyde until analysis within 24 hr. The 
expression of CD107, IL- 2, IL- 10, IL- 17, TNFalpha, IFNgamma, and 
MIP- 1beta was measured as described previously. Flow cytometry 
data were acquired and analyzed as described above.
2.6 | Immunohistochemistry of endometrium
At the time of collection, a portion of each endometrial biopsy was 
fixed in formalin and paraffin embedded (Table 3; Fig. 5). Five- micron 
sections were stained with mouse monoclonal antibodies against 
human CD4 (clone 4B12, 1:10 dilution; ThermoFisher, Rockford, IL, 
USA); CD8 (clone c8/144B, 1:50 dilution; ThermoFisher); CD56, a 
marker of NK cells (clone 123c3.d5, 1:100 dilution; ThermoFisher); 
CD68, a marker of macrophages (clone KP1, 1:100 dilution; DAKO, 
Carpinteria, CA, USA); and FoxP3, a marker of regulatory T cells 
(clone 123c3.d5, 1:50 dilution; ThermoFisher) using previously pub-
lished techniques.19–21 Peroxidase- conjugated goat anti- mouse sec-
ondary antibodies (1:200 dilution; Vector Laboratories, Burlingame, 
CA, USA) and diaminobenzidine substrate (DAKO, kit as directed) 
were used for detection of antibody binding. Each analysis included 
an appropriate negative control using mouse IgG1 or IgG2a (DAKO). 
Photomicrographs of randomly selected fields using the 40× objec-
tive of an Olympus BX51 microscope were captured using a CCD 
camera (Spot Camera; Diagnostic Instruments, Sterling Heights, MI, 
USA). Positively stained cells were counted on photomicrographs of 
up 5–10 fields from each slide. As the tissue in the photomicrograph 
did not always fill the field, the area that contained tissue was out-
lined and measured on a grid; counts represent the number of stained 
cells divided by the number of grids included in the image. Tissue are-
as covering more than 96 grids (of a total possible 382.5 grids) were 
included in the analysis. To avoid counting projections from a single 
CD68+ cell as multiple cells, CD68 staining had to be associated with 
a nucleus to be counted as a CD68+ cell. To be counted as a FoxP3+ 
cell, the staining had to be nuclear.
2.7 | Statistical methods
2.7.1 | Participant characteristics
We summarized and compared characteristics of study participants 
by exposure group (Table 1). For continuous characteristics (age and 
duration of current LNG- IUD exposure), we report median (min, max) 
and Wilcoxon rank- sum test P- values. For categorical characteristics 
(race, smoking status, and ovulation status), we report percentages 
per group and Fisher’s exact test P- values.
F IGURE  3 A summary of flow cytometric phenotyping 
data. Bivariate distributions of three pairs of phenotypes, (a) 
CCR7/CD45RA, (b) CD38/HLADR, and (c) CXCR4/CCR5, are 
summarized for CD4+ and CD8+ T cells from endocervical cytobrush 
and endometrium, as indicated in the figure headings. The stacked 
box plots summarize the distribution of each phenotype, analyzed 
as a function of exposure group (control or LNG- IUD) in models 
stratified by tissue and cell type. P- values <.05 are shown in red 
type. Color coding follows the same pattern in all graphs: +/− 
blue, −/+ yellow, +/+ green, −/− gray. TEMRA indicates terminally 
differentiated effector cells expressing CD45RA
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2.7.2 | Wick analyses
Wick sampling and processing yielded one observation per biomarker 
per participant (Fig. 1). Preliminary histograms revealed that distribu-
tions of protein concentrations (pg/mL) of all biomarkers measured 
were right- skewed; consequently, concentrations were analyzed as 
linear functions of exposure group (LNG- IUD vs unexposed) and age 
(centered at 30 years old) using generalized estimating equation (GEE) 
models, assuming negative binomial distributions and using a log link 
F IGURE  4 Panel (a) intracellular cytokine production by CD4+ and CD8+ T cells following polyclonal stimulation. For analysis of endometrial 
T- cell responses to stimulation, production of six cytokines (IFN- γ, IL- 2, IL- 10, IL- 17, MIP- 1β, and TNF- α) and the granule- associated membrane 
protein CD107 were measured by flow cytometry as described in the text. Initial gating was performed to identify lymphocytes and remove 
doublets (not shown), followed by gating of viable CD3+ T cells on subsets expressing either CD4 or CD8, and finally for individual responses as 
indicated on bivariate plots. Numbers indicate the percentages of CD4+ or CD8+ T cells in each quadrant. Data shown are from a representative 
participant using LNG- IUD with SEB- stimulated cells. Panel (b) production of IL- 10 by CD4+ and CD8+ T cells from endometrial tissue of LNG- 
IUD users (“IUD”) and control women (“REF”) following stimulation with PMA–ionomycin (blue boxes, left) or SEB (red boxes, right). Box plots 
illustrate the percent responding cells by subject group, cell type, and stimulus. The length of each box represents the interquartile range (IQR; 
the distance between the 25th and 75th percentiles), and the interior line represents the median (50th percentile). A symbol (diamond) denotes 
the mean. “Whiskers” are drawn to the most extreme observations that lie within the fences. The upper fence is defined as the third quartile plus 
1.5 times the interquartile range (IQR), and the lower fence is defined as the first quartile minus 1.5 times the interquartile range. Observations 
outside the fences are identified with small circles
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and robust standard errors. Age- adjusted group- specific mean (95% 
CI) concentrations per biomarker were plotted side- by- side, sorted by 
concentrations in the control group. The corresponding age- adjusted 
exposure effects, expressed as a mean (95% CI) relative concentration 
(fold- change) among exposed versus unexposed participants, were 
plotted in the same order. We also report Wald statistic P- values from 
the GEE analyses.
2.7.3 | Flow cytometry
Flow cytometry assays, based one endocervical and one endometrial 
sample per participant, generated person- level bivariate distributions 
of three pairs of phenotypes—CCR7/CD45RA, CD38/HLADR, and 
CXCR4/CCR5—separately for CD4+ and CD8+ cell types (Fig. 3). The 
distribution of each phenotype was analyzed as a function of expo-
sure group in models stratified by tissue and cell type. Using SAS logis-
tic with a glogit link, each person- level distribution was analyzed as a 
multinomial outcome, which constrains component percentages (e.g., 
of CCR7+/CD45RA+, CCR7+/CD45RA−, CCR7−/CD45RA+, and 
CCR7−/CD45RA−) to sum to 100%. Using SAS genmod with a normal 
link and accounting for repeated measures per participant, identical 
mean estimates were obtained by modeling component percentages 
as a function of exposure group, component level, and their interac-
tion. We report three degree- of- freedom interaction- effect P- values 
TABLE  1 Baseline demographic and eligibility characteristics by 
study group
Characteristic Control (n=27) LNG- IUD (n=19)
P 
valuesa
Age, median (min, 
max)
34.4 (23.4, 44.3) 26.8 (18.7, 44.4) .0028
Race, Number (%)
White/Caucasian 18 (66.7%) 10 (52.6%) .22
Black/African 
American
7 (26.0%) 5 (26.3%)
Native American 0 (0.0%) 1 (5.3%)
Asian/Pacific 
Islander
2 (7.7%) 1 (5.3%)
Other/Mixed 0 (0.0%) 2 (10.5%)
Current smoking, 
Number (%)
9 (33.3%) 2 (10.5%) .19
Proportion ovulated, 
Number (%)b
25 (93) 5 (45) .003
Months of LNG- IUD 
exposure, median 
(interquartile range)
15.3 (10–25)
aData presented as a median was analyzed with a Wilcoxon rank- sum test, 
and data presented as N (%) was analyzed with the Fisher’s exact test.
bOvulation defined as a serum progesterone of greater than or equal to 
2 mg/mL, based on progesterone measurements in all 25 control partici-
pants and for 11/19 LNG- IUD participants.
F IGURE  5  Immunohistochemical 
detection of regulatory T cells in 
endometrial biopsies. Five- micron paraffin 
sections of formalin- fixed endometrial 
biopsies from control participants panels 
(a and b) and LNG- IUD users panels 
(c and d) were incubated with mouse 
monoclonal anti- FoxP3 antibodies 
followed by peroxidase- conjugated goat 
anti- mouse secondary antibodies and 
diaminobenzidine substrate, as described 
in Methods. Slides were counterstained 
with hematoxylin. Dark brown nuclear 
staining reflects the presence of FoxP3. 
Enlarged views of rectangular areas 
outlined in panel (b) and (d) are shown 
from the same slide panels (b1 and d1) or 
from a serial section incubated without 
anti- FoxP3 antibodies panels (b2 and d2). 
Bar in panel (a) = 100 μm
(a) (c)
(b)
(b1) (b2)
(d)
(d1) (d2)
CONTROL LNG-IUD
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generated by the latter model which are based on empiric standard 
errors. We present these results via plots of the mean bivariate distri-
butions by cell type, tissue, and arm (Fig. 3).
2.7.4 | Immune mediators
Studies of the effects of stimulation of CD4+ and CD8+ cells from 
endometrial tissue by PMA–ionomycin or Staphylococcal enterotoxin 
B (SEB) yielded four observations per immune mediator per partici-
pant, expressed as percentages (Table 2; Fig. 4). We used GEE mod-
els, assuming negative binomial distributions and using log links and 
empirical standard errors. Each model expressed log percentage of a 
phenotype as a linear function of exposure group, stimulant, and their 
interaction, stratified by cell type. For each biomarker, we report the 
mean (95% CI) percentage in the control group and the mean (95% CI) 
exposure effect, expressed as the ratio (fold- change) among exposed 
versus unexposed participants (Table 2). Finally, we present box plots 
of the raw data per exposure group for biomarker IL- 10 to allow com-
parison of model- based findings with raw data (Fig. 4b).
2.7.5 | Immune cell densities
For each specimen per participant, biomarker cell counts were 
determined in multiple standardized areas (see Methods for 
Immunohistochemistry above) (Table 3). Only participants with 5–10 
qualifying areas were included in the analysis, generating different 
sample sizes per marker. Counts of each biomarker were analyzed as 
above (negative binomial distribution, logarithm link, robust variance 
estimator) as a function of study group; additionally, an offset used to 
adjust for the sizes of the areas counted. Results were transformed 
back to the measurement scale for reporting.
Statistical analyses were conducted using SAS version 9.4. All 
 P- values cited are two- sided and values less than α = .05 were consid-
ered statistically significant.
3  | RESULTS
3.1 | Demographics
Nineteen LNG- IUD users and 27 control women were included in the 
study (Table 1). LNG- IUD users were younger than control women 
(27 years vs 34 years, P=.004). The majority of women in both groups 
identified as white (53% LNG- IUD users and 67% controls) or black 
(26% in both groups). LNG- IUD users were less likely to smoke tobacco 
than controls (11% vs 33%), but this difference did not reach statistical 
significance (P=.19). The median serum progesterone concentration 
was lower among LNG- IUD users compared to controls (0.7 ng/mL vs 
7.7 ng/mL, P=.03), perhaps due to less frequent ovulation among the 
LNG- IUD users (45% vs 93% of controls, P=.003). The median dura-
tion of LNG- IUD use was 15.3 months (interquartile range 10–25).
TABLE  2  (A) Endometrial CD4+ T- cell responses to stimulation, ordered by decreasing level among control group, based on samples from 26 
participantsa. (B) Endometrial CD8+ T cell responses to stimulation, ordered as in (A), based on samples from 26 participantsb
Factor
PMA and Ionomycin Staphylococcal Enterotoxin B (SEB)
Controlc
Mean (95% CI)
LNG- IUD: Controld
Mean (95% CI) P- value
Controlc
Mean (95% CI)
LNG- IUD: Controld
Mean (95% CI) P- value
(A)
TNFalpha 24.5 (14.0–42.8) 0.93 (0.35–2.51) .89 20.1 (14.6–27.6) 1.36 (0.82–2.24) .23
IFNgamma 26.4 (15.9–43.8) 0.73 (0.26–2.06) .55 17.5 (12.9–23.7) 1.09 (0.74–1.62) .66
IL2 19.4 (11.5–32.7) 0.84 (0.31–2.31) .74 14.1 (10.5–18.8) 1.3 (0.88–1.98) .19
MIP1beta 13.1 (7.2–24.0) 0.64 (0.27–1.52) .31 7.74 (4.80–12.5) 0.91 (0.51–1.60) .73
CD107 10.5 (5.88–18.8) 0.23 (0.11–0.48) <.0001 5.87 (3.55–9.69) 0.66 (0.25–1.72) .39
IL- 17 1.06 (0.51–2.19) 2.67 (0.89–8.05) .081 2.17 (1.15–4.12) 1.79 (0.71–4.52) .21
IL- 10 0.96 (0.26–3.52) 5.58 (1.11–28.0) .04 0.96 (0.58–1.59) 6.05 (2.66–13.8) <.0001
(B)
TNFalpha 24.6 (14.0–43.4) 0.43 (0.18–1.02) .06 20.5 (14.7–28.6) 0.65 (0.39–1.07) .09
IFNgamma 34.7 (21.7–55.4) 0.83 (0.34–1.99) .67 22.5 (16.4–31.0) 0.81 (0.54–1.21) .30
IL2 18.9 (10.5–34.0) 0.65 (0.21–2.05) .46 10.2 (6.33–16.3) 0.72 (0.40–1.30) .27
MIP1beta 31.8 (19.1–52.8) 1.08 (0.53–2.20) .83 18.6 (12.6–27.3) 0.96 (0.57–1.60) .88
CD107 20.0 (13.7–29.2) 0.60 (0.28–1.31) .20 18.6 (13.7–25.2) 0.81 (0.50–1.30) .38
IL17 1.47 (0.46–4.65) 3.3 (0.74–14.7) .12 1.55 (0.46–5.26) 2.58 (0.56–11.8) .22
IL10 1.02 (0.33–3.19) 5.20 (1.13–23.9) .03 0.55 (0.17–1.81) 10.7 (2.48–46.4) .002
CI, Confidence interval.
aPMA and ionomycin results are based on n=13 samples for control and n=7 for LNG- IUD; SEB results are based on n=16 samples for control and n=10 for 
LNG- IUD.
bPMA and ionomycin results are based on n=12 samples for Control and n=7 for LNG- IUD; SEB results are based on n=15 samples for Control and n=10 
for LNG- IUD.
cPercent of cells expressing factor among controls.
dRelative percent comparing LNG- IUD to controls (fold- change). Results that are statistically significant with P value ≤.05 are shown in boldface with 
italics.
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3.2 | Effects of LNG- IUD use on chemokines, 
cytokine, and innate immune factors in the 
endocervical canal
To determine whether LNG- IUD altered the immune milieu of the 
endocervix, we studied concentrations of 13 proteins in endocervical 
fluid in samples from 19 LNG- IUD users and 24 control women (Fig. 1). 
In general, protein concentrations were elevated among IUD users rel-
ative to controls, with statistically significant age- adjusted effects for 
6 of 13 endocervical cytokine and chemokine levels. Comparing LNG- 
IUD users with control women, significant effects were identified for 
MCP1 (IUD:control fold- change 5.97, P<.001), TNFalpha (fold- change 
2.83, P<.001), IL- 1beta (fold- change 2.63, P=.047), IFNgamma (fold- 
change 1.96, P=.005), IL- 12 (fold- change 1.94, P=.025), and IFNalpha2 
(fold- change 1.62, P=.02). Two other 95% CIs almost exceeded 1.0 
(IL- 8 and MIP1alpha). Finally, age was significantly associated with 
only two protein levels, MIP1beta and TNFalpha, and controlling for 
age dampened the corresponding IUD effects. These results indicate 
that LNG- IUD use is associated with significant increases in soluble 
inflammatory immune modulators within the endocervical canal.
3.3 | Effects of LNG- IUD use on the phenotype 
distributions of endocervical T cells
Representative flow cytometry gating used in the analysis of endocer-
vical and endometrial T- cell phenotypes is shown in Fig. 2. To deter-
mine whether LNG- IUD use was associated with changes in immune 
characteristics of the T cells present in endocervix, the cell surface 
markers on CD4+ and CD8+ T- cell subsets collected via endocervical 
brushings from 25 controls and 17 IUD users were analyzed by flow 
cytometry (Fig. 3). In previous studies, we found that when compared 
with T cells in peripheral blood, a greater proportion of endocervical 
T cells were activated, effector memory cells,18 a pattern we again 
observed among samples from control women from this study (data 
not shown). The proportion of CD4+ T cells co- expressing both HIV 
co- receptors (CXCR4+CCR5+) was increased among LNG- IUD users 
compared to controls. (Fig. 3c). For both CD4+ and CD8+ T cells, 
the proportion expressing markers of the central memory compart-
ment (CCR7+CD45RA−) was reduced among LNG- IUD users com-
pared to controls (Fig. 3a). In addition, endocervical CD8+ T cells 
from LNG- IUD users demonstrated an increase in the proportion of 
cells expressing the activation marker HLADR (CD38- HLADR+ and 
CD38+HLDR+) (Fig. 3b).
3.4 | Effects of LNG- IUD use on the phenotype 
distributions of endometrial T cells
To determine whether LNG- IUD use was associated with changes 
in immune characteristics of the T cells present in endometrium, the 
cell surface markers on CD4+ and CD8+ (Figs 2 and 3) T cell subsets 
collected via endometrial biopsies from 16 women per group were 
analyzed by flow cytometry. In endometrium obtained from control 
women, >50% of CD4+ T cells expressed markers of an effector mem-
ory phenotype as well as CD38 and CCR5, as previously reported.18 
In samples from LNG- IUD users, the proportions of endometrial CD4+ 
T cells expressing the activation marker HLADR were increased com-
pared with controls (CD38− HLADR+ and CD38+ HLADR+), whereas 
the proportions of CD4+ T cells expressing CD38 were decreased 
(CD38+ HLADR−) (Fig. 3b). The proportions of endometrial CD4+ 
T cells expressing the HIV co- receptor CXCR4 were significantly 
increased (CXCR4+ CCR5−, CXCR4+ CCR5+), whereas those express-
ing CCR5 without CXCR4 expression were decreased (CXCR4− CCR5+) 
(Fig. 3c).
For CD8+ T cells, the proportions of endometrial cells expressing 
the activation marker HLADR were increased (CD38− HLADR+ and 
CD38+ HLADR+), whereas the proportion of CD8+ T cells expressing 
CD38 without HLADR was decreased (CD38+ HLADR−). The propor-
tions of CD8+ T cells expressing the HIV co- receptor CXCR4 were 
significantly increased (CXCR4+ CCR5−, CXCR4+ CCR5+) among LNG- 
IUD users, whereas the proportion expressing CCR5 without CXCR4 
was decreased (CXCR4− CCR5+).
Figure 3 also allows the T- cell distribution to be compared between 
the endocervix and the endometrium. As reported previously, T- cell 
phenotypes in the two tissues are markedly different despite their 
anatomic proximity.18 By comparing the graphs from control partici-
pants for cervix and endometrium, it is apparent that endocervix had 
significantly greater proportions of naïve, central memory, and termi-
nally differentiated effector CD4+ T cells, as well as higher proportions 
of naïve and terminally differentiated effector CD8+ T cells than T cells 
recovered from the endometrium (Fig. 3a). However, endometrium 
had a significantly higher proportion of activated CD4+ and CD8+ T 
cells (CD38+ HLADR+) than endocervix (Fig. 3b). With regard to the 
distribution of T cells that expressed HIV co- receptors, the proportions 
TABLE  3 Quantification of cell types by immunohistochemistry in 
endometrial biopsy specimens, based on samples from 28 
participants
Cell type 
(Antibody)
Control 
Mean cell densitya 
(95% CI)
LNG- IUD: Controlb
Fold change 
(95% CI) P- value
NK cell (CD56) 71.2 (30.0, 168.7) 
n=10c
1.54 (0.63, 3.80) 
n=11d
.35
Macrophage 
(CD68)
55.4 (38.0, 80.6) 
n=12
1.45 (0.93, 2.24) 
n=11
.098
T cell (CD8) 18.8 (11.5, 30.8) 
n=12
2.63 (1.39, 5.01)
n=11
.003
T cell (CD4) 9.7 (6.0, 15.5) 
n=9
2.35 (1.21, 4.59)
n=5
.012
Regulatory T cell 
(FoxP3)
5.54 (3.54, 8.68) 
n=11
3.52 (2.04, 6.09)
n=14
<.0001
CI, Confidence interval.
aDensity is defined as the number of positively stained cells in a standard-
ized unit of area from photographic images of 40× microscopic fields.
bResults that are statistically significant with P value ≤.05 are shown in 
boldface with italics.
cn = the number of control samples analyzed.
dn = the number of LNG- IUD samples analyzed.
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of CD4+ and CD8+ T cells expressing CCR5 (CXCR4− CCR5+ and 
CXCR4CCR5+) were higher in the endometrium (Fig. 3c).
3.5 | Effects of LNG- IUD use on the response of 
endometrial T cells to stimulation
To determine whether the function of endometrial T cells differed 
between the LNG- IUD users and control women, we analyzed intra-
cellular expression of soluble immune mediators for CD4+ (Table 2A) 
and CD8+ (Table 2B) T cells after stimulation with PMA–ionomycin 
or SEB. Representative flow cytometry gating used in the analysis of 
intracellular cytokine production from endometrial T cells is shown 
in Fig. 4a. In samples from control study participants, after PMA–
ionomycin activation, >20% of CD4+ T cells expressed TNFalpha 
and IFNgamma, and ≥20% of CD8+ T cells expressed MIP1beta, 
IFNgamma, TNFalpha, and CD107 (Table 2). In contrast, ≤2% of either 
CD4+ or CD8+ T cells expressed IL- 17 or IL- 10 after activation.
Compared to samples from control participants, samples from 
LNG- IUD users showed reduced expression of CD107 by CD4+ T cells 
upon PMA–ionomycin activation. In contrast, both CD4+ and CD8+ 
T cells from IUD users showed markedly increased production of IL- 
10 compared to samples from control participants upon activation by 
either stimulant, with the fold- increase ranging from 5.2 to 10.7- fold 
(Table 2A and B and Fig. 4b).
3.6 | Effects of LNG- IUD use on densities of immune 
cells in the endometrium
To determine whether the quantity of key immune cell types in endo-
metrium differed between LNG- IUD users and control women, we 
performed IHC on endometrial biopsy tissue sections using markers 
for NK cells (CD56), macrophages (CD68), T cells (CD4+ and CD8+), 
and regulatory T cells (FoxP3) (Table 3). In endometrium from control 
women, NK cells were present at the highest densities, followed by 
macrophages. CD8+ T cells were present at approximately twice the 
density of CD4+ T cells. FoxP3+ regulatory T cells were the least com-
mon cell type, at a density that could account for approximately half 
of the population of CD4+ T cells in the endometrium.
In endometrial samples obtained from LNG- IUD users, the 
densities of NK cells and macrophages were comparable to con-
trols (Table 3). However, the densities of all T- cell populations were 
increased in LNG- IUD users, led by a >threefold increase in regulatory 
T cells. Examples of IHC staining for FoxP3 in control and LNG- IUD 
endometrial biopsies are shown in Fig. 5.
4  | DISCUSSION
Our results from control participants not using hormonal con-
traceptives or IUDs provide important normative data about the 
immune microenvironment of the upper female reproductive tract. 
In the endocervix, chemokines (IL- 8, MCP1) and proinflammatory 
cytokines (IL- 1alpha, IL- 6) are present at high concentrations (ng/mL), 
likely reflecting the role of the cervix in preventing passage of vagi-
nal microflora into the uterus. Our results also highlight important 
differences between the endocervical and endometrial microenvi-
ronments. For example, CD4+ T cells expressing activation markers 
(CD38+ HLADR+) and the HIV co- receptor relevant for mucosal HIV 
transmission (CCR5+) are both significantly more abundant in the 
endometrium than in the endocervix, whereas naïve, central memory, 
and terminally differentiated effector CD4+ T cells are more abundant 
in the endocervix than the endometrium. These results emphasize the 
importance of considering each compartment independently in stud-
ies related to HIV susceptibility.
Our results indicate that significant differences were identified in 
the immune microenvironment of the upper female reproductive tract 
in LNG- IUD users. In the endocervical canal, LNG- IUD use was asso-
ciated with significantly increased concentrations of several inflamma-
tory cytokines (TNFalpha, IL- 1beta, IFNgamma, IL- 12, and IFNalpha2) 
and a chemokine (MCP1). By virtue of the method of sample collec-
tion, we were unable to determine the cellular origin of the cyto-
kines: endocervical cells, infiltrating immune cells, or both. However, 
as endocervical T cells in samples from LNG- IUD users were more 
likely to express activation markers (CD38+ HLADR+) than samples 
from controls, some of these proteins were likely derived from local 
activated immune cells. While the implications of our findings for HIV 
susceptibility are unknown, the observed higher chemokine concen-
trations in LNG- IUD users could result in recruitment of HIV target 
cells and hence increase HIV susceptibility. Conversely, the observed 
up- regulation of inflammatory cytokines could instead indicate a 
robust local innate immune response that might increase protection 
against viral infection.
Increased IL- 10 levels in the endocervix have been associated 
with the presence of sexually transmitted infections,22 which are in 
turn linked to increased HIV acquisition. Our results did not demon-
strate a significant increase IL- 10 levels in endocervical fluid of LNG- 
IUD users, which is reassuring in terms of HIV risk. However, we did 
observe a change in HIV target cells in the endocervix; although there 
was no change in the proportion of CD4+/CXCR4− CCR5+ T cells in 
LNG- IUD users, there was an increase in CD4+ T cells expressing both 
CXCR4+ and CCR5+. Given that transmitted HIV virions are predomi-
nantly CCR5 tropic, and that the columnar epithelium of the endocer-
vix is considered a favored site for HIV transmission, our finding of an 
increased proportion of HIV target cells at that site may have import-
ant implications for HIV susceptibility in LNG- IUD users.
Our results indicate that use of the LNG- IUD was associated with 
increased expression on endometrial T cells of the HIV co- receptor 
CXCR4 and decreased expression of CCR5. These results are similar 
to those reported by a study of the effects of LNG- IUD and cop-
per IUD on endometrial T cells 2 months after IUD insertion, which 
showed decreased expression of CCR5 in the endometrium of LNG- 
IUD users.23 Participants of our study had been exposed to LNG- IUDs 
for a much longer period of time; all had used the LNG- IUD for at 
least 6 months, with median use time of 15 months, indicating that 
the reduction in CCR5+ endometrial T cells observed after 2 months 
of device use was sustained over longer periods of use. As in the 
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endocervix, we did observe an increase in the endometrium of CD4+ 
T cells expressing both CXCR4+ and CCR5+. Endometrial macrophages 
have also been shown to be a potentially important target for HIV 
infection24; hence, it is reassuring that our results also did not demon-
strate an increased density of macrophages in the endometrium of 
LNG- IUD users.
The presence of a foreign body such as the IUD in the uterus may 
result in an inflammatory response and constitute a primary mech-
anism for preventing pregnancy.10–12 Indeed, our results indicate 
that a higher proportion of CD4+ and CD8+ T cells co- expressing the 
activation markers CD38 and HLADR are present in the endometri-
um of LNG- IUD users compared to controls, suggesting a response 
to local perturbations either from the IUD itself or the local release 
of LNG. In addition, transcriptional profiling of endometrial samples 
from participants of this study (previously published) revealed that 
the endometrial transcriptome in LNG- IUD users is characterized by 
marked up- regulation of pathways regulated by inflammatory medi-
ators TNFalpha, IL- 1beta, and NFkappaB.25 Regulatory T cells are 
often recruited in response to and in order to control local effects 
of chronic inflammation. Indeed, our immunohistochemical analysis 
showed significantly increased numbers of regulatory T cells in the 
endometrium in LNG- IUD users compared to controls. In addition, 
we found that activation of endometrial T cells was associated with 
increased production of the immunosuppressive cytokine IL- 10 in 
LNG- IUD users. These results indicate that the endometrium of LNG- 
IUD users is poised more for a Th2 (immunosuppressive) than a Th1 
(cytotoxic) response compared to controls, perhaps indicating that the 
endometrium employs compensatory mechanisms to regulate chronic 
inflammation induced by the presence of a foreign body. Furthermore, 
while the role of IL- 10 in HIV susceptibility and disease progression 
is likely complex, polymorphisms associated with decreased IL- 10 
production have been associated with increased susceptibility to HIV 
infection.26 Therefore, the elevated levels of IL- 10 after immune acti-
vation in LNG- IUD users in this study may indicate an HIV- protective 
mechanism.
The strengths of our study are the wide range of immune param-
eters that were measured, and the collection of samples from com-
parison participants timed to a narrow window of the ovulatory cycle, 
thus minimizing the effects of ovarian sex steroid variations on our 
findings. In addition, by enrolling women who had chronic exposure to 
the LNG- IUD, we were able to characterize the impact of this IUD in 
a timeframe that better mirrors actual use than post- insertion obser-
vations. This study is limited by relatively small numbers of individuals 
and samples analyzed, the fact that absence of recent sexual activity 
was documented by self- report only, and that the LNG- IUD group had 
a lower percentage of women who had ovulated compared to con-
trols. Ultrasound studies have demonstrated that ovulation occurs in 
a subset of women using the LNG- IUD.27 We assume that the local 
release of LNG would dominate any effects of progesterone released 
cyclically in the women who ovulated, but were unable to determine 
whether the release of progesterone from ovulation might have con-
tributed to our findings, or perhaps masked a larger effect from the 
LNG- IUD had we controlled for this variable. Additionally, we cannot 
infer the effects of LNG- IUD directly as we did not study women prior 
to and after device insertion. We were unable to determine wheth-
er our results reflect the presence of a foreign body versus the local 
release of LNG in the endometrium. Comparison of effects of the 
copper (non- hormonal) IUD to those of LNG- IUD will help distinguish 
between these possibilities.
Our results indicate LNG- IUD use resulted in both inflammatory 
and immunosuppressive changes (the latter being perhaps compen-
satory in nature) in the local immune microenvironment of the endo-
cervix and endometrium. Further research is needed to determine the 
effects of these changes on HIV infection of target cells from LNG- 
IUD users, and on overall risk of HIV acquisition.
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